© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Biosimilars
COVID-19 May Continue to Impact Healthcare Costs
February 01, 2021
Biosimilars may reduce healthcare costs.
While We Await Vaccine Progress, We Can Trust in Generic Drugs
February 01, 2021
Generic drugs account for 90% of the prescriptions filled in the United States. They are the backbone of healthcare providers’ treatment protocol and they are remarkably cost effective: despite being 90% of the prescriptions filled, generics account for only 20% of drug spending.
MHE’s Most-Read Oncology News in 2020
December 29, 2020
Drug and diagnostic approvals and biosimilars news were popular with readers.
Talking Biosimilars With OneOncology’s Dr. Jeff Patton
October 31, 2020
The leading community oncology practice partnership has been an early adopter of biosimilars, and a trouble-shooter for hurdles with payers.
To Beat High Costs, California Moves to Create Its Own Drug Label
September 30, 2020
Health Plan Group Puts Biosimilars On Its Roadmap of Needed Healthcare Reforms
September 28, 2020
The Alliance of Community Health Plans calls for changes to get more biosimilars approved and on the market.
Proliferation of Biosimilars Could Be Costly for Oncologists, Warns Texas Oncology Policy Leader
September 28, 2020
Texas Oncology Executive Vice President Debra Patt says it will be unrealistically expensive for oncologists to keep many biosimilars for the same innovator product in their inventories.
The Benefits of Anti-TNF Biosimilars
August 18, 2020
Authors of a review say biosimilars would improve treatment, not just reduce cost.
Oncology Care Model Spurs Use of Biosimilar Filgrastim
August 17, 2020
Whether the OCM has worked out is debatable, but it has apparently encouraged the use of biosimilar versions of filgrastim.
When Will Biosimilars Start Making a Serious Difference in Oncology?
August 05, 2020
It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's evidence of some effect on the price of cancer supportive drugs.